A5070606803- Complement system in diseases
- Platelet Disorders and Treatments
- Blood groups and transfusion
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Renal Diseases and Glomerulopathies
- Iron Metabolism and Disorders
- Hemoglobinopathies and Related Disorders
- Hemophilia Treatment and Research
- Blood donation and transfusion practices
- Blood Coagulation and Thrombosis Mechanisms
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood properties and coagulation
- Blood transfusion and management
- Porphyrin Metabolism and Disorders
- Immune Cell Function and Interaction
- Folate and B Vitamins Research
- Cystic Fibrosis Research Advances
- Neonatal Health and Biochemistry
- Urticaria and Related Conditions
- Viral Infections and Immunology Research
- Heme Oxygenase-1 and Carbon Monoxide
- Vitamin C and Antioxidants Research
- Diabetes Treatment and Management
- Teratomas and Epidermoid Cysts
- Vascular Anomalies and Treatments
University of Minnesota
2017-2025
University of Minnesota System
2022-2024
University of Miami
2023
University of Minnesota Medical Center
2020-2022
University of North Carolina at Chapel Hill
2012-2020
University of North Carolina Health Care
2012-2015
University of North Carolina Hospitals
2013
Duke University
2013
Key Points Joint hemorrhages and orthopedic procedures are more frequent in patients with hemophilia A than those B. FA levels of 20% may be required to prevent all joint hemorrhages.
Background: Erythropoietic protoporphyria (EPP) and X-linked (XLP) are characterized by the accumulation of protoporphyrin in marrow, erythrocytes, plasma, skin, liver, present clinically with painful cutaneous phototoxicity. Liver abnormalities have been reported over 25% patients EPP. Further characterization liver involvement is needed. Methods: Patients EPP or XLP enrolled longitudinal studies NIH-supported Porphyrias Consortium were included. Medical history, laboratory, histology data...
Background Transfusion‐associated circulatory overload ( TACO ) is the second leading cause of reported transfusion‐related fatalities in United States. While its occurrence has been previously investigated after red cell and plasma transfusion, no data are available regarding association with platelet transfusion. Our goal was to determine rate platelet‐associated at our university medical centre. Study Design Methods This study had retrospective prospective analyses. The 13‐year analysis...
Levy, Cynthia; Dickey, Amy K.; Wang, Bruce; Thapar, Manish; Naik, Hetanshi; Keel, Siobán B.; Saberi, Behnam; Beaven, Simon W.; Rudnick, Sean R.; Elmariah, Sarina Erwin, Angelika L.; Goddu, Robert J.; Hedstrom, Karli; Leaf, Rebecca Karp; Kazamel, Mohamed; Mazepa, Marshall; Philpotts, Lisa Liang; Quigley, John; Raef, Haya; Ungar, Jonathan; Anderson, Karl E.; Balwani, Manisha; on behalf of the Porphyrias Consortium Rare Diseases Clinical Network. Author Information
The anti-Von Willebrand Factor (VWF) nanobody caplacizumab is licensed for adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP) in association therapeutic plasma exchange (TPE) and immunosuppression. However, whether reduces mortality, its optimal timing of initiation, not completely settled. This international, multicenter retrospective cohort study recruited patients from 2018 until 2023 data collection took place January 1st to June 30th the participating centers. One...
Background/Objectives: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, chronically relapsing disorder that causes life-threatening microangiopathy. Many survivors in clinical remission show evidence of ongoing silent cerebral infarction and neurocognitive deficits. Prospective longitudinal studies this population are needed to acquire complete understanding the mechanism behind neurologic injury. We aimed assess feasibility multicenter prospective study neuropsychological...
The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes ITP with bortezomib, a proteasome inhibitor. strategy has been successful in relapsing thrombotic thrombocytopenic but is novel therapeutic approach for ITP. Further research use inhibition may warranted.
Bleeding heterogeneity amongst patients with immune thrombocytopenia (ITP) is poorly understood. Platelets play a role in maintaining endothelial integrity, and variable thrombocytopenia-induced changes may influence bleeding severity. Platelet-derived stabilizers markers of integrity ITP are largely underexplored. We hypothesized that, canine model, would lead to alterations the ultrastructure that Von Willebrand factor (vWF) serve as marker injury associated thrombocytopenia....
Cardiovascular disease is a leading cause of death in survivors immune-mediated thrombotic thrombocytopenic purpura (iTTP), but the epidemiology major adverse cardiovascular events (MACE) iTTP unknown. We evaluated prevalence and risk factors for MACE, defined as composite non-fatal or fatal myocardial infarction (MI), stroke, cardiac revascularization, during clinical remission two large cohorts (Johns Hopkins University Ohio State University). Of 181 patients followed ≥ 3 months after...
The purpose of this survey was to describe current practices in the U.S. for treatment acquired Thrombotic Thrombocytopenic Purpura (TTP), compare these with prior and Canadian practices, identify areas clinical equipoise.A research team member administered by telephone. Questions included an estimate annual patient volume treated, apheresis medical therapy TTP.32 centers from 22 states were surveyed. ADAMTS13 activity is used confirmation diagnosis TTP (97%). Most commonly, daily plasma...
Acquired thrombotic thrombocytopenic purpura (TTP) is a disease characterized by microangiopathic hemolytic anemia and thrombocytopenia, in addition to variable fever neurologic renal dysfunction, without an underlying cause. Recent advances elucidating the pathophysiology of acquired TTP have led new testing that we incorporated into our current management patients with suspected TTP. Despite these developments, much treatment for beyond therapeutic plasma exchange (TPE) based on...
Mortality due to immune-mediated thrombotic thrombocytopenic purpura (iTTP) remains significant. Predicting mortality risk may potentially help individualize treatment. The French Thrombotic Microangiopathy (TMA) Reference Score has not been externally validated in the United States. Recent advances machine learning technology can analyze large numbers of variables with complex interactions for development prediction models.